• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于水疱性口炎病毒的抗拉沙病毒和埃博拉病毒疫苗。

Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.

作者信息

Marzi Andrea, Feldmann Friederike, Geisbert Thomas W, Feldmann Heinz, Safronetz David

出版信息

Emerg Infect Dis. 2015 Feb;21(2):305-7. doi: 10.3201/eid2102.141649.

DOI:10.3201/eid2102.141649
PMID:25625358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4313664/
Abstract

We demonstrated that previous vaccination with a vesicular stomatitis virus (VSV)-based Lassa virus vaccine does not alter protective efficacy of subsequent vaccination with a VSV-based Ebola virus vaccine. These findings demonstrate the utility of VSV-based vaccines against divergent viral pathogens, even when preexisting immunity to the vaccine vector is present.

摘要

我们证明，先前接种基于水疱性口炎病毒（VSV）的拉沙病毒疫苗不会改变随后接种基于VSV的埃博拉病毒疫苗的保护效力。这些发现证明了基于VSV的疫苗对不同病毒病原体的效用，即使存在对疫苗载体的预先免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43c9/4313664/f2d17c17c43d/14-1649-F.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43c9/4313664/f2d17c17c43d/14-1649-F.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43c9/4313664/f2d17c17c43d/14-1649-F.jpg

相似文献

1
Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.基于水疱性口炎病毒的抗拉沙病毒和埃博拉病毒疫苗。
Emerg Infect Dis. 2015 Feb;21(2):305-7. doi: 10.3201/eid2102.141649.
2
DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.DNA 疫苗可诱导豚鼠对拉沙病毒和埃博拉病毒的个体或同时感染产生持久的保护性免疫。
Hum Vaccin Immunother. 2017 Dec 2;13(12):3010-3019. doi: 10.1080/21645515.2017.1382780. Epub 2017 Nov 14.
3
Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.重组 DNA 衍生的拉沙病毒和丝状病毒疫苗的研究进展。
Virus Res. 2011 Dec;162(1-2):148-61. doi: 10.1016/j.virusres.2011.09.005. Epub 2011 Sep 10.
4
Virology. New vaccine and treatment excite Ebola researchers.病毒学。新型疫苗与疗法令埃博拉研究人员兴奋不已。
Science. 2003 Nov 14;302(5648):1141-2. doi: 10.1126/science.302.5648.1141.
5
Evaluating Temperature Sensitivity of Vesicular Stomatitis Virus-Based Vaccines.评估基于水泡性口炎病毒的疫苗的温度敏感性。
Emerg Infect Dis. 2019 Aug;25(8):1563-1566. doi: 10.3201/eid2508.190281. Epub 2019 Aug 17.
6
A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.一种基于重组水疱性口炎病毒的拉沙热疫苗可保护豚鼠和猕猴免受地理和基因上不同的拉沙病毒的攻击。
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736. doi: 10.1371/journal.pntd.0003736. eCollection 2015 Apr.
7
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.基于水泡性口炎病毒的疫苗可保护非人灵长类动物免受埃博拉病毒和马尔堡病毒的气溶胶攻击。
Vaccine. 2008 Dec 9;26(52):6894-900. doi: 10.1016/j.vaccine.2008.09.082. Epub 2008 Oct 18.
8
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.基于甲病毒复制子的单价和二价疫苗可保护豚鼠免受拉沙病毒和埃博拉病毒感染。
J Virol. 2001 Dec;75(23):11677-85. doi: 10.1128/JVI.75.23.11677-11685.2001.
9
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.针对埃博拉、苏丹、马尔堡和拉萨热病毒的多病原体疫苗具有强大的免疫原性和保护效力。
PLoS Pathog. 2024 Jun 26;20(6):e1012262. doi: 10.1371/journal.ppat.1012262. eCollection 2024 Jun.
10
Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.基于水疱性口炎病毒的苏丹病毒疫苗的种属特异性免疫原性和保护效力：猕猴挑战研究。
Lancet Microbe. 2023 Mar;4(3):e171-e178. doi: 10.1016/S2666-5247(23)00001-0. Epub 2023 Feb 2.

引用本文的文献

1
Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein.使用mRNA和rVSV平台的同源和异源疫苗接种方案可诱导针对发热伴血小板减少综合征病毒糖蛋白的强效免疫反应。
Viruses. 2025 Aug 8;17(8):1095. doi: 10.3390/v17081095.
2
Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge.单剂量基于水疱性口炎病毒的疫苗可保护小鼠免受致死性异源克里米亚-刚果出血热病毒攻击。
NPJ Vaccines. 2025 May 30;10(1):109. doi: 10.1038/s41541-025-01164-3.
3
Mapping the antibody response to Lassa virus vaccination of non-human primates.

本文引用的文献

1
Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections.西非埃博拉病毒病——疫情头9个月及未来预测
N Engl J Med. 2014 Oct 16;371(16):1481-95. doi: 10.1056/NEJMoa1411100. Epub 2014 Sep 22.
2
Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.单剂量减毒尼帕病毒疫苗通过诱导针对表面糖蛋白的抗体来提供完全保护。
Vaccine. 2014 May 7;32(22):2637-44. doi: 10.1016/j.vaccine.2014.02.087. Epub 2014 Mar 12.
3
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
绘制非人灵长类动物对拉沙病毒疫苗接种的抗体反应图谱。
EBioMedicine. 2025 Apr;114:105673. doi: 10.1016/j.ebiom.2025.105673. Epub 2025 Mar 31.
4
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.一种具有复制能力的基于水疱性口炎病毒的拉沙病毒候选疫苗的临床前开发已推进到人体临床试验阶段。
EBioMedicine. 2025 Apr;114:105647. doi: 10.1016/j.ebiom.2025.105647. Epub 2025 Mar 28.
5
Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats.为生物医学高级研究与发展管理局应对威胁制造病毒载体疫苗的战略和技术考量
Vaccines (Basel). 2025 Jan 14;13(1):73. doi: 10.3390/vaccines13010073.
6
Current perspectives on vaccines and therapeutics for Lassa Fever.拉沙热疫苗与治疗方法的当前观点
Virol J. 2024 Dec 19;21(1):320. doi: 10.1186/s12985-024-02585-7.
7
Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.2023年9月22日SPEAC网络研讨会报告：感音神经性听力损失、拉沙病毒病与疫苗
Vaccine. 2025 Jan 1;43(Pt 1):126525. doi: 10.1016/j.vaccine.2024.126525. Epub 2024 Nov 22.
8
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.新发和再发传染病：全球趋势及预防和控制新策略。
Signal Transduct Target Ther. 2024 Sep 11;9(1):223. doi: 10.1038/s41392-024-01917-x.
9
The Importance of Lassa Fever and Its Disease Management in West Africa.拉沙热的重要性及其在西非的疾病管理。
Viruses. 2024 Feb 7;16(2):266. doi: 10.3390/v16020266.
10
Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus.单剂量基于重组水疱性口炎病毒的疫苗可引发针对汉坦病毒的强大且持久的中和抗体。
NPJ Vaccines. 2024 Feb 10;9(1):28. doi: 10.1038/s41541-024-00814-2.
基于水疱性口炎病毒的疫苗可保护非人灵长类动物免受本迪布焦埃博拉病毒感染。
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.
4
Vaccines for viral hemorrhagic fevers--progress and shortcomings.病毒性出血热疫苗——进展与不足。
Curr Opin Virol. 2013 Jun;3(3):343-51. doi: 10.1016/j.coviro.2013.04.007. Epub 2013 Jun 15.
5
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.抗体对于 rVSV/ZEBOV-GP 介导的非人类灵长类动物抵抗致死性埃博拉病毒攻击的保护是必要的。
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.
6
A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.马里最近分离出的拉沙病毒表现出非典型的临床疾病表现，并降低了食蟹猴的毒力。
J Infect Dis. 2013 Apr 15;207(8):1316-27. doi: 10.1093/infdis/jit004. Epub 2013 Jan 9.
7
Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.基于水疱性口炎病毒的疫苗可保护仓鼠免受安第斯病毒的致死性攻击。
J Virol. 2011 Dec;85(23):12781-91. doi: 10.1128/JVI.00794-11. Epub 2011 Sep 14.
8
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.单次注射疫苗可保护非人灵长类动物免受马尔堡病毒和三种埃博拉病毒的感染。
J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.
9
Development of a new vaccine for the prevention of Lassa fever.开发一种预防拉沙热的新型疫苗。
PLoS Med. 2005 Jun;2(6):e183. doi: 10.1371/journal.pmed.0020183. Epub 2005 Jun 28.
10
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.减毒活重组疫苗可保护非人灵长类动物免受埃博拉病毒和马尔堡病毒感染。
Nat Med. 2005 Jul;11(7):786-90. doi: 10.1038/nm1258. Epub 2005 Jun 5.